Top Institutional Investors

Prosight Management, LP — 13F Holdings & Portfolio

CIK 1617201 · latest 13F-HR filed 2026-08-14

Backtest portfolio

Prosight Management, LP manages $580.4M in 13F-reported U.S. long-equity assets across 36 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are LKFT (10.56%), JANX (10.07%), NKTR (9.74%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 5 new positions and exited 15; 17 existing positions rose in reported value and 13 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$580.4M

Long-equity book

Holdings
36

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+5 / −15 / ↑17 / ↓13

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26
LKFT10.6% · newJANX10.1% · +7%NKTR9.7% · +10%BSX9.3% · +60%STTK7.1% · +19%INSM6.9% · newALNY5.1% · +29%SNDX4.5% · +56%KURA3.8% · -40%ALKS3.6% · -23%IRTC3.4% · +1555%VEEV3.2% · +23%ZYME3.0% · +25%ABVX2.5% · +2%CRNX2.4% · +7%MLYS2.1% · newADCT1.4% · -6%ICUI1.3% · +86%ISRG1.2% · +325%CRBP1.1% · -7%PRCT1.0% · -86%WGS1.0% · -84%OPCH1.0% · newOKUR0.8% · -55%EBS0.7% · -28%PFE0.6% · newKIDS0.5% · -48%RCKT0.4% · +2%ANTX0.4% · -8%PLRX0.3% · -18%TECX0.2% · -50%MGTX0.2% · -97%EFOR0.2% · newRNTX0.2% · +167%COYA0.2% · -60%IMRX0.0% · -70%

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 70.7%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 30, 2026.

Assets Under Management
$1.04B
Discretionary
$1.04B
Employees
5
Accounts
6
Address
5956 SHERRY LANE
SUITE 1365
DALLAS, TX 75225
Phone
(214) 468-0008
Website
Name Title / Status Ownership Type
CAPPELLI, RYAN, MATTHEW ControlCHIEF COMPLIANCE OFFICER / CHIEF OPERATING OFFICER
since Jun 2016
Less than 5%Individual
HAWKINS, WILLIAM, LAWRENCE ControlSOLE MEMBER / MANAGING PARTNER
since Oct 2008
75% or moreIndividual
PROSIGHT PARTNERS, LLC ControlGENERAL PARTNER OF PROSIGHT MANAGEMENT, LP
since Nov 2008
Less than 5%Domestic Entity
HAWKINS, WILLIAM, LAWRENCE Control
Indirect owner via PROSIGHT PARTNERS LLC
SOLE MEMBER OF PROSIGHT PARTNERS LLC
since Nov 2008
75% or moreIndividual

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Prosight Management, LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 LAKEFRONT BIOTHERAPEUTICS NV LKFT 36315X101 $61.3M 10.56% 2,043,344 SH
2 JANUX THERAPEUTICS INC JANX 47103J105 $58.4M 10.07% 3,804,481 SH
3 NEKTAR THERAPEUTICS NKTR 640268306 $56.5M 9.74% 810,000 SH
4 BOSTON SCIENTIFIC CORP BSX 101137107 $54.2M 9.34% 1,270,273 SH
5 SHATTUCK LABS INC STTK 82024L103 $41.3M 7.12% 5,957,877 SH
6 INSMED INC INSM 457669307 $40.0M 6.90% 375,609 SH
7 ALNYLAM PHARMACEUTICALS INC ALNY 02043Q107 $29.5M 5.09% 98,080 SH
8 SYNDAX PHARMACEUTICALS INC SNDX 87164F105 $26.2M 4.52% 1,200,000 SH
9 KURA ONCOLOGY INC KURA 50127T109 $22.2M 3.82% 2,021,964 SH
10 ALKERMES PLC ALKS G01767105 $20.7M 3.56% 394,389 SH
11 IRHYTHM HOLDINGS INC IRTC 450056106 $19.7M 3.39% 165,500 SH
12 VEEVA SYS INC VEEV 922475108 $18.8M 3.25% 106,200 SH
13 ZYMEWORKS INC ZYME 98985Y108 $17.6M 3.04% 674,434 SH
14 ABIVAX SA ABVX 00370M103 $14.3M 2.47% 107,394 SH
15 CRINETICS PHARMACEUTICALS IN CRNX 22663K107 $14.0M 2.42% 374,666 SH
16 MINERALYS THERAPEUTICS INC MLYS 603170101 $12.1M 2.09% 449,795 SH
17 ADC THERAPEUTICS SA ADCT H0036K147 $8.4M 1.44% 7,824,749 SH
18 ICU MED INC ICUI 44930G107 $7.5M 1.29% 51,000 SH
19 INTUITIVE SURGICAL INC ISRG 46120E602 $6.8M 1.16% 17,000 SH
20 CORBUS PHARMACEUTICALS HLDGS CRBP 21833P301 $6.1M 1.05% 650,000 SH
21 PROCEPT BIOROBOTICS CORP PRCT 74276L105 $6.1M 1.04% 268,269 SH
22 GENEDX HOLDINGS CORP WGS 81663L200 $5.9M 1.01% 85,500 SH
23 OPTION CARE HEALTH INC OPCH 68404L201 $5.7M 0.98% 270,716 SH
24 ONKURE THERAPEUTICS INC OKUR 68277Q105 $4.5M 0.77% 978,992 SH
25 EMERGENT BIOSOLUTIONS INC EBS 29089Q105 $3.9M 0.66% 459,952 SH
26 PFIZER INC PFE 717081103 $3.3M 0.56% 135,366 SH
27 ORTHOPEDIATRICS CORP KIDS 68752L100 $3.0M 0.52% 157,500 SH
28 ROCKET PHARMACEUTICALS INC RCKT 77313F106 $2.4M 0.41% 700,000 SH
29 AN2 THERAPEUTICS INC ANTX 037326105 $2.3M 0.40% 474,638 SH
30 PLIANT THERAPEUTICS INC PLRX 729139105 $1.6M 0.27% 1,370,233 SH
31 TECTONIC THERAPEUTIC INC TECX 878972108 $1.4M 0.24% 39,731 SH
32 MEIRAGTX HLDGS PLC MGTX G59665102 $1.2M 0.21% 90,000 SH
33 EVERFORTH INC EFOR 00191U102 $1.2M 0.21% 67,500 SH
34 REIN THERAPEUTICS INC RNTX 00887A204 $1.1M 0.20% 1,100,000 SH
35 COYA THERAPEUTICS INC COYA 22407B108 $994.5K 0.17% 170,000 SH
36 IMMUNEERING CORP IMRX 45254E107 $183.9K 0.03% 36,861 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $580.4M 36 0001420506-26-001799
2026-03-31 2026-05-15 $609.8M 46 0001420506-26-001036
2025-12-31 2026-02-13 $483.9M 38 0001420506-26-000422
2025-09-30 2025-11-14 $428.8M 44 0001420506-25-003233
Filer Information
Address
5956 SHERRY LANE
SUITE 1365
DALLAS, TX 75225
Phone
(214) 468-0008
Filing Manager
Prosight Management, LP
DALLAS, TX
Signatory
Ryan Cappelli
Chief Compliance Officer/Chief Operating Officer